The Activity of FDA-Approved Prodrug Isavuconazonium Sulfate and Its Major Metabolite Isavuconazole Against Naegleria fowleri
Open Access
- 12 January 2026
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (1) , 103
Abstract
Objectives: Free-living amoeba Naegleria fowleri causes primary amoebic meningoencephalitis (PAM). While infection is rare, PAM’s fatality rate exceeds 97%. The recommended treatment includes combination therapy, which does not result in uniform survival. Thus, there is a critical unmet need for finding better therapy for PAM. Drug repurposing can expedite the discovery of effective treatment for PAM. Isavuconazonium is approved for the treatment of fungal infections. Given that isavuconazole is the major metabolite of isavuconazonium and isavuconazole penetrates into the brain with high efficiency, our objective was to determine the activity of both isavuconazonium and isavuconazole on N. fowleri trophozoites. Methods: To test the effect of both compounds, we determined their dose–responses against N. fowleri and two mammalian cells. To establish how fast the prodrug and the metabolite kill the trophozoites, we measured potency at different time points. Finally, we investigated the effect of combining isavuconazonium or isavuconazole with amphotericin B on both N. fowleri and mammalian cells. Results: Both isavuconazonium and the metabolite isavuconazole were active against multiple strains, with clinically relevant isavuconazole exhibiting potency ranging between 0.1 and 0.6 µM. They were less toxic on mammalian cells. Isavuconazonium and isavuconazole required 24 h to achieve nanomolar potency. Combination with amphotericin B was synergistic without eliciting toxicity on mammalian cells. Conclusions: Our findings, together with the use of intravenous and oral formulations of isavuconazonium to treat pediatric and adult patients, support further in vivo efficacy study of isavuconazonium for its potential use for the treatment of PAM.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases of the National Institutes of Health (R21AI171538)
This publication has 48 references indexed in Scilit:
- Advancing the understanding of Naegleria fowleri: Global epidemiology, phylogenetic analysis, and strategies to combat a deadly pathogenJournal of Infection and Public Health, 2025
- Primary amebic meningoencephalitis: a review of Naegleria fowleri and analysis of successfully treated casesParasitology Research, 2024
- Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Isavuconazonium SulfateJournal of Pharmaceutical Sciences, 2023
- High-Throughput Screen of Microbial Metabolites Identifies F1FO ATP Synthase Inhibitors as New Leads for Naegleria fowleri InfectionACS Infectious Diseases, 2023
- The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug ClearanceClinical Pharmacology & Therapeutics, 2017
- Characterization of butyrylcholinesterase in bovine serumChemico-Biological Interactions, 2017
- Biology and pathogenesis of Naegleria fowleriActa Tropica, 2016
- Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal AgentPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2015
- The epidemiology of primary amoebic meningoencephalitis in the USA, 1962–2008Epidemiology and Infection, 2009
- Successful Treatment of Naegleria fowleri Meningoencephalitis by Using Intravenous Amphotericin B, Fluconazole and RifampicinArchives of Medical Research, 2005